within Pharmacolibrary.Drugs.ATC.V;

model V10AX02
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 1.6666666666666667e-08,
    adminDuration  = 600,
    adminMass      = 185 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 1e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>V10AX02</td></tr><td>route:</td><td>intraarticular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Samarium (153Sm) hydroxyapatite colloid is a radiopharmaceutical agent used primarily in the treatment of pain due to bone metastases and in radiosynovectomy for joint disorders. The hydroxyapatite colloid acts as a carrier for the radioactive 153Sm, which localizes in bone or intra-articular space to deliver targeted radiation. The use of 153Sm hydroxyapatite is mostly restricted to specific clinical settings and is not widely approved for all indications or available in all countries.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic parameters found for samarium (153Sm) hydroxyapatite colloid in humans. Estimates are based on general knowledge of radiocolloid pharmacokinetics for intra-articular or intraosseous administration.</p><h4>References</h4><ol><li><p>Couto, RM, et al., &amp; De Araújo, EB (2010). In vivo comparative study of hydroxyapatite labeled with different radioisotopes: evaluation of the scintigraphic images. <i>Cellular and molecular biology (Noisy-le-Grand, France)</i> 56(2) 6–11. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20525452/&quot;>https://pubmed.ncbi.nlm.nih.gov/20525452</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end V10AX02;
